
A study assessed the efficacy of P2Y12 inhibitor monotherapy versus 12-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stents. Among 1387 patients, P2Y12 inhibitor monotherapy after 3 months of DAPT was non-inferior to 12-month DAPT for net adverse clinical events. Major bleeding occurred less frequently with P2Y12 inhibitor monotherapy. These findings suggest that P2Y12 inhibitor monotherapy may offer a comparable alternative to prolonged DAPT in patients undergoing PCI with the latest drug-eluting stents.
Like
Save
Share